Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Links shared publicly online about this topic.

1,508
total visits

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacterem

View full resource at news-medical.net

Tags: Pneumonia, Pneumococcal Disease, Pneumococcal Vaccine, Disease and Condition, Protein, Children's Health, Vaccine, Prevnar